Can CAR T-cells Be Made Inside the Body? Major Multiple Myeloma Breakthroughs from ASH 2025 скачать в хорошем качестве

Can CAR T-cells Be Made Inside the Body? Major Multiple Myeloma Breakthroughs from ASH 2025

CAR T-cell therapy has transformed multiple myeloma treatment and new research from ASH 2025 may make it safer, more effective, and more accessible. In this video, Dr. Joseph Mikhael, Chief Medical Office of the International Myeloma Foundation reviews the top five CAR T-cell therapy updates presented at the American Society of Hematology, including in vivo CAR T manufacturing, long-term Carvykti (cilta-cel) results, improved safety through bridging therapy, dual-target CAR T, and Abecma's (anito-cel) 96% response rate. If you or a loved one is exploring CAR T for multiple myeloma, this research could shape the future of treatment. Topics Covered in this Video: 0:00 - CAR T-cell therapy overview in multiple myeloma 0:46 - In vivo CAR T: Manufacturing CAR-T cells inside the body 1:41 - Long-term Carvykti (cilta-cel) remission data in standard-risk myeloma 2:23 - Safety: Bridging therapy & reducing delayed neurotoxicity risk 3:08 - Go deeper into the science with the IMWG Conference Series 3:38 - Dual-target CAR T (AZD0120) in frontline therapy 4:31 - Abecma (anito-cel): 96% response rate & safety findings Read more about these research updates in Dr. Joe's blog: https://www.myeloma.org/blog/dr-mikha... Have a question that needs more personalized support? Call us! We’re here for you. The IMF’s InfoLine is available to answer your myeloma-related questions and concerns. Call us at 1-818-487-7455, email us at infoline@myeloma.org, or schedule your call at a time that works best for you at: https://www.myeloma.org/infoline. _______________ Founded in 1990, the International Myeloma Foundation (IMF) is the world’s leading organization dedicated to multiple myeloma. The IMF is steadfast in its mission: improving the quality of life of myeloma patients while working toward prevention and a cure. The IMF serves people impacted by myeloma at every stage of the disease by combining world-class research, trusted education, global advocacy, and direct support. A cornerstone of this work is the International Myeloma Working Group® (IMWG)—a network of more than 300 internationally renowned researchers and clinicians who establish the guidelines that shape how myeloma is diagnosed, treated, and managed across the globe. Through its global network of support groups, educational programs, its 24/7 generative-AI myeloma assistant Myelo®, its InfoLine staff, and its advocacy for greater healthcare access, the IMF helps people living with myeloma and their care partners navigate diagnosis, treatment, and survivorship. At the same time, the IMF ensures scientific advances translate into better care and outcomes. The IMF is driven by its vision: A world where every myeloma patient can live life to the fullest, unburdened by the disease. Learn more at www.myeloma.org or contact the IMF InfoLine at (800) 452-CURE (2873) (U.S. & Canada), +1 (818) 487-7455 (worldwide), or infoline@myeloma.org. Subscribe to our channel:    / imfmyeloma   Find us online: Facebook: @myeloma |   / myeloma   X/Twitter: @IMFMyeloma |   / imfmyeloma   Instagram: @imfmyeloma |   / imfmyeloma   LinkedIn:   / international-myeloma-foundation   Support the IMF | Donate Now! https://fundraise.myeloma.org/give/52... Category Nonprofits & Activism License Standard YouTube License The International Myeloma Foundation is committed to accessibility for all. That’s why all English-language videos uploaded to our YouTube channel feature human-transcribed closed captioning. This ensures more accurate captions for viewers who are Deaf or hard of hearing and improves the quality of automatic translations into other languages for our global audience.